Clinical trial
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of…
NCT00384930 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00384930 |
|---|---|
| Title | Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | ICOS Corporation Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | tadalafil, placebo |
| Enrollment | 1,058 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | Oct 6, 2006 |
| Last update posted | Sep 2, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: